ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in Atlanta, GA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Renal Cell Carcinoma
Lung Cancer
Triple Negative Breast Cancer

Melanoma trials near Atlanta, GA, USA:

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass)

efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma...

Enrolling
Ocular Melanoma
Choroidal Melanoma
Device: Suprachoroidal Microinjector
Drug: Bel-sar

Phase 3

Aura Biosciences
Aura Biosciences

Atlanta, Georgia, United States and 51 other locations

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

To evaluate the overall survival of HLA-A\*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investig...

Active, not recruiting
Uveal Melanoma
Biological: IMCgp100
Biological: Pembrolizumab

Phase 2

Immunocore
Immunocore

Atlanta, Georgia, United States and 55 other locations

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

participants with a type of skin cancer known as melanoma.The objective of this study is to see if the combination of fianlimab and cemipli...

Enrolling
Melanoma
Drug: pembrolizumab
Drug: cemiplimab

Phase 2, Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Atlanta, Georgia, United States and 24 other locations

Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

immune related adverse events in participants with stage III-IV melanoma that cannot be removed by surgery who are undergoing nivolumab and ...

Active, not recruiting
Cutaneous Melanoma, Stage III
Stage IIIA Skin Melanoma
Drug: Ipilimumab
Drug: Nivolumab

Phase 2

Emory University
Emory University

Atlanta, Georgia, United States

IDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma

antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotin...

Enrolling
Metastatic Uveal Melanoma
Drug: IDE196
Drug: Nivolumab

Phase 2, Phase 3

Ideaya Biosciences

Atlanta, Georgia, United States and 65 other locations

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC...

Active, not recruiting
Melanoma
Drug: nivolumab+rHuPH20
Drug: relatlimab+nivolumab

Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Atlanta, Georgia, United States and 31 other locations

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma (RELATIVITY-098)

to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma...

Active, not recruiting
Melanoma
Biological: Nivolumab
Biological: Nivolumab + Relatlimab Fixed Dose Combination

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Atlanta, Georgia, United States and 183 other locations

VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma

and/or nivolumab work in treating participants with stage IIIB-D melanoma that can be removed by surgery. Monoclonal antibodies, such as VX1...

Active, not recruiting
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Biological: Ipilimumab
Biological: VX15/2503

Phase 1

Emory University
Emory University

Atlanta, Georgia, United States

Locations recently updated

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma (RP2-202)

of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy....

Enrolling
Metastatic Uveal Melanoma
Biological: RP2
Biological: Nivolumab

Phase 2, Phase 3

Replimune

Atlanta, Georgia, United States and 11 other locations

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma (CheckMate76K)

and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recur...

Active, not recruiting
Melanoma
Other: Placebo
Biological: Nivolumab

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Atlanta, Georgia, United States and 128 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems